OR WAIT null SECS
Although the year may be winding to a close, the diabetes community has still been moving ahead at a breakneck pace. In a year marked by historic advances, including the approval of tirzepatide (Mounjaro) and teplizumab (Tzield), the month of December has played host to the long-awaited US FDA clearance of the Dexcom G7 Continuous Glucose Monitoring System, the American Diabetes Association’s annual update of their Standards of Care in Diabetes, and the Association of Diabetes Care and Education Specialists (ADCES) Diabetes Technology Conference.
To bring the year to a close, the hosts of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives Diana Isaacs, PharmD, an endocrine clinical pharmacist and coordinator of the CGM Program Coordinator at the Cleveland Clinic, and Natalie Bellini, DNP, an endocrine nurse practitioner at R&B Medical Group, sat down to discuss recent developments in the field, with a spotlight on the Dexcom G7 CGM, key takeaways from the ADA’s Standards of Care in Diabetes—2023, and perspective from the ADCES Diabetes Technology Conference 2022.
Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is available in an audio-only format on Spotify and Apple Podcasts.